For research teamsHelp me find a study
Back to all studies
CompletedNCT01692782

SEP-225289 for ADHD

This study is completed in the United States. It is testing SEP-225289 for ADHD.

ADHDDrugFrom 18 Years to 55 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether SEP-225289 Versus Placebo may be useful for adults experiencing ADHD.

What would participation involve?

Participants may receive SEP-225289 Versus Placebo, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.

Who is it mainly for?

This study appears to be mainly for adults with ADHD.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateDecember 2012
Recruitment status
Completed
Enrollment listed in the registry
341
Sponsor
Sumitomo Pharma America, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT01692782
Official title
A Randomized, Double Blind, Parallel Group, Multicenter Efficacy and Safety Study of SEP-225289 Versus Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

United States · 31 sites
  • Pharmacology Research Institute
    Encino, California
    Site status: Not listed — confirm with the team
  • Collaborative Neuroscience Network Inc
    Garden Grove, California
    Site status: Not listed — confirm with the team
  • University of California at Irvine
    Irvine, California
    Site status: Not listed — confirm with the team
  • Pharmacology Research Institute
    Los Alamitos, California
    Site status: Not listed — confirm with the team
  • Pharmacology Research Institute
    Newport Beach, California
    Site status: Not listed — confirm with the team
  • Excell Research, Inc
    Oceanside, California
    Site status: Not listed — confirm with the team
  • Neuropsychiatric Research Center of Orange County
    Santa Ana, California
    Site status: Not listed — confirm with the team
  • Florida Clinical Research Center, LLC
    Bradenton, Florida
    Site status: Not listed — confirm with the team
  • Clinical Neuroscience Solutions Inc.
    Jacksonville, Florida
    Site status: Not listed — confirm with the team
  • Florida Research Center
    Maitland, Florida
    Site status: Not listed — confirm with the team
  • Miami Research Associates
    Miami, Florida
    Site status: Not listed — confirm with the team
  • Research Centers of America, LLC
    Oakland Park, Florida
    Site status: Not listed — confirm with the team
  • Medical Research Group of Central Florida
    Sanford, Florida
    Site status: Not listed — confirm with the team
  • Atlanta Center for Medical Research
    Atlanta, Georgia
    Site status: Not listed — confirm with the team
  • iResearch Atlanta, LLC
    Decatur, Georgia
    Site status: Not listed — confirm with the team
  • Goldpoint Clinical Research
    Indianapolis, Indiana
    Site status: Not listed — confirm with the team
  • IPS Research Company
    Oklahoma City, Indiana
    Site status: Not listed — confirm with the team
  • Rochester Center for Behavioral Health
    Rochester Hills, Michigan
    Site status: Not listed — confirm with the team
  • Midwest Research Group
    Saint Charles, Missouri
    Site status: Not listed — confirm with the team
  • Center for Emotional Fitness
    Cherry Hill, New Jersey
    Site status: Not listed — confirm with the team
  • Brooklyn Medical Institutes, LLC
    Brooklyn, New York
    Site status: Not listed — confirm with the team
  • Duke Child and Family Study Center
    Durham, North Carolina
    Site status: Not listed — confirm with the team
  • Midwest Clinical Research Center
    Dayton, Ohio
    Site status: Not listed — confirm with the team
  • Oregon Center for Clinical Investigations, Inc.
    Portland, Oregon
    Site status: Not listed — confirm with the team
  • Suburban Research Associates
    Media, Pennsylvania
    Site status: Not listed — confirm with the team
  • CRI Lifetree
    Philadelphia, Pennsylvania
    Site status: Not listed — confirm with the team
  • Clinical Neuroscience Solutions
    Memphis, Tennessee
    Site status: Not listed — confirm with the team
  • Future Search Clinical Trials, LP
    Austine, Texas
    Site status: Not listed — confirm with the team
  • NeuroScience, Inc
    Herndon, Virginia
    Site status: Not listed — confirm with the team
  • Eastside Therapeutic Resource
    Kirkland, Washington
    Site status: Not listed — confirm with the team
  • Summit Research Network, LLC-Seattle
    Seattle, Washington
    Site status: Not listed — confirm with the team

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT01692782. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving SEP-225289, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.

Who might this study be for?

This study may concern people with adhd; age range: From 18 Years to 55 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Sumitomo Pharma America, Inc., which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.